group. (n= 215) p-value. Demographics. Age (at indication onset), mean (sd) *. 72.58. (10.03). 72.15. (12.45). 0.79. 73.01. (10.30). 0.85. Gender (female), n (%)*.
Table S3: Balance in variables before and after propensity score matching – CHF subgroup in STRIDE Variable
Demographics Age (at indication onset), mean (sd) * Gender (female), n (%)* Race, n (%)* Asian Black Native American Unknown White Comorbidities Diabetes, n (%)* Dyslipidemias, n (%) Hypertension, n (%) Renal failure, n (%) Co-prescriptions Statins, n (%)* Beta blocking agents, n (%) ACE inhibitors, plain, n (%)* Antiplatelet drugs, n (%) Aspirin, n (%)* Clopidogrel, n (%)* Warfarin, n (%)* Antiarryhtmics, n (%)* Diabetes drugs, n (%)* History of Arrhythmias, n (%)* Tachycardia, n (%) Atrial fibrillation, n (%) Ventricular tachycardia, n (%) Ventricular fibrillation, n (%) Conduction disease and/or bradyarrythmia, n (%) MACE, n (%)*† Myocardial infarction, n (%) Stroke, n (%)* Defibrillation event, n (%)* Cardiac arrest, n (%)* Sudden cardiac death, n (%) MALE, n (%)† Revascularization, n (%)* Bypass, n (%)* Angioplasty, n (%)* Amputation, n (%)*
Before Matching
After PSM matching
Cilostazol group (n= 43)
Unmatched PAD patients (n= 1213)
p-value
Matched control group (n= 215)
p-value
72.58 (10.03) 27.91
72.15 (12.45) 42.95
0.79
0.85
0.04
73.01 (10.30) 29.30
4.65 2.33 0.41 24.14 58.14
8.66 5.60 0.00 35.81 59.60
0.24 0.18 0.03 0.34 0.85
3.26 0.93 0.00 35.81 59.01
0.75 0.61 1.00 0.75 0.93
34.88 69.77 88.37 9.05
33.64 58.94 85.74 7.78
0.87 0.14 0.60 0.51
32.56 73.49 87.91 8.88
0.82 0.68 0.95 0.95
81.40 88.37 70.07
61.50 68.67 75.10
